Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease.

Nakamuta M, Fujino T, Yada R, Yada M, Yasutake K, Yoshimoto T, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Enjoji M.

Int J Mol Med. 2009 May;23(5):603-8.

PMID:
19360318
2.

Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.

Quinet EM, Savio DA, Halpern AR, Chen L, Schuster GU, Gustafsson JA, Basso MD, Nambi P.

Mol Pharmacol. 2006 Oct;70(4):1340-9. Epub 2006 Jul 6.

3.

The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression.

Pawar A, Botolin D, Mangelsdorf DJ, Jump DB.

J Biol Chem. 2003 Oct 17;278(42):40736-43. Epub 2003 Aug 13.

4.

SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.

Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R, Nakamuta M.

Int J Mol Med. 2008 Apr;21(4):507-11.

PMID:
18360697
5.

Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta.

Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ.

Genes Dev. 2000 Nov 15;14(22):2819-30.

6.

5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.

Xu L, Kim JK, Bai Q, Zhang X, Kakiyama G, Min HK, Sanyal AJ, Pandak WM, Ren S.

Mol Pharmacol. 2013 Mar;83(3):648-58. doi: 10.1124/mol.112.081505. Epub 2012 Dec 20.

7.

Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.

Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Takayanagi R, Nakamuta M.

Int J Mol Med. 2007 Sep;20(3):351-8.

PMID:
17671740
8.

Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.

Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanyal AJ.

Cell Metab. 2012 May 2;15(5):665-74. doi: 10.1016/j.cmet.2012.04.004.

10.

Induction of SREBP-1c mRNA by differentiation and LXR ligand in human keratinocytes.

Yokoyama A, Makishima M, Choi M, Cho Y, Nishida S, Hashimoto Y, Terui T.

J Invest Dermatol. 2009 Jun;129(6):1395-401. doi: 10.1038/jid.2009.15. Epub 2009 Feb 26.

11.

Suppression of 2,3-oxidosqualene cyclase by high fat diet contributes to liver X receptor-alpha-mediated improvement of hepatic lipid profile.

Dang H, Liu Y, Pang W, Li C, Wang N, Shyy JY, Zhu Y.

J Biol Chem. 2009 Mar 6;284(10):6218-26. doi: 10.1074/jbc.M803702200. Epub 2009 Jan 1.

12.
13.

Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling.

Ronis MJ, Chen Y, Badeaux J, Badger TM.

J Nutr. 2009 Aug;139(8):1431-8. doi: 10.3945/jn.109.107029. Epub 2009 Jun 10.

14.

Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice.

Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z.

Hepatology. 2008 Sep;48(3):770-81. doi: 10.1002/hep.22423.

PMID:
18752326
15.

Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease.

Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M.

Hepatol Res. 2008;38(11):1122-9. doi: 10.1111/j.1872-034X.2008.00382.x. Epub 2008 Jul 28.

PMID:
18684130
16.

Trans geometric isomers of EPA decrease LXRalpha-induced cellular triacylglycerol via suppression of SREBP-1c and PGC-1beta.

Zaima N, Sugawara T, Goto D, Hirata T.

J Lipid Res. 2006 Dec;47(12):2712-7. Epub 2006 Sep 27.

17.

Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.

Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S.

Clin Sci (Lond). 2011 Mar;120(6):239-50. doi: 10.1042/CS20100387.

PMID:
20929443
18.

Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.

Yoshikawa T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Yatoh S, Kitamine T, Okazaki H, Tamura Y, Sekiya M, Takahashi A, Hasty AH, Sato R, Sone H, Osuga J, Ishibashi S, Yamada N.

Mol Endocrinol. 2003 Jul;17(7):1240-54. Epub 2003 May 1.

PMID:
12730331
20.

Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver.

Yamamoto T, Shimano H, Inoue N, Nakagawa Y, Matsuzaka T, Takahashi A, Yahagi N, Sone H, Suzuki H, Toyoshima H, Yamada N.

J Biol Chem. 2007 Apr 20;282(16):11687-95. Epub 2007 Feb 12.

Supplemental Content

Support Center